PTC Therapeutics, Inc.(NASDAQ : PTCT)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.24%||69.51||1.0%||$508.61m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.82%||202.78||1.9%||$475.09m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.10%||627.03||2.7%||$468.82m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-2.57%||4.17||0.7%||$291.50m|
|EXAS||EXACT Sciences Corp.||-5.37%||76.25||18.0%||$147.69m|
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.